Moleculin Biotech ownership reported at 4.99%

Moleculin Biotech, Inc. is the subject of a Schedule 13G reporting the ownership of common stock by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC.

Rhea-AI Filing Summary

Moleculin Biotech, Inc. is the subject of a Schedule 13G reporting the ownership of common stock by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of the close of business on August 6, 2025, they may be deemed to beneficially own 973,927 shares of common stock, representing approximately 4.99% of the class. This total includes 203,720 shares held by Intracoastal and 770,207 shares issuable upon exercise of a warrant referred to as Intracoastal Warrant 2, all calculated against a base of 7,100,713 shares outstanding as of July 30, 2026 plus additional shares issued in connection with a Securities Purchase Agreement.

The filing describes prior ownership immediately following execution of the Securities Purchase Agreement on July 31, 2026, when the reporting persons may have been deemed to beneficially own 788,091 shares (about 9.99% of the common stock) including shares to be issued and shares issuable upon exercise of a warrant. Both Intracoastal Warrant 1 and Intracoastal Warrant 2 contain blocker provisions limiting exercisability so that beneficial ownership does not exceed 9.99% or 4.99%, respectively. Without these blocker provisions, the reporting persons may have been deemed to beneficially own up to 5,333,332 shares immediately following the agreement and 4,203,719 shares as of August 6, 2025. The filing states that they now report ownership of 5 percent or less of the class.

Key Figures

Current beneficial ownership: 973,927 shares of common stock Current ownership percentage: 4.99% Shares held outright: 203,720 shares of common stock +5 more

8 metrics

Current beneficial ownership 973,927 shares of common stock May be deemed beneficially owned by the reporting persons as of August 6, 2025

Current ownership percentage 4.99% Percent of Moleculin Biotech common stock class beneficially owned

Shares held outright 203,720 shares of common stock Shares of Moleculin Biotech common stock held by Intracoastal

Warrant 2 shares included 770,207 shares of common stock Shares issuable upon exercise of Intracoastal Warrant 2 included in 4.99% stake

Shares outstanding baseline 7,100,713 shares of common stock Shares outstanding as of July 30, 2026, used in ownership calculations

Initial post-SPA ownership 788,091 shares of common stock Beneficially owned immediately following July 31, 2026 Securities Purchase Agreement

Initial potential ownership without blockers 5,333,332 shares of common stock Maximum shares that may have been deemed owned immediately after SPA without blockers

Current potential ownership without blockers 4,203,719 shares of common stock Maximum shares that may have been deemed owned as of August 6, 2025 without blockers

Key Terms

Securities Purchase Agreement, beneficial ownership, blocker provision, dispositive power, +1 more

5 terms

Securities Purchase Agreement financial

"Immediately following the execution of the Securities Purchase Agreement with the Issuer"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

beneficial ownership financial

"each of the Reporting Persons may have been deemed to have beneficial ownership of 788,091 shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

blocker provision financial

"Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right"

dispositive power financial

"Shared Dispositive Power 948,927.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"Ownership of 5 Percent or Less of a Class. | Ownership of 5 percent or less of a class"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Moleculin Biotech (MBRX) does Intracoastal Capital report owning?

Intracoastal Capital and its affiliates report beneficial ownership of 973,927 shares of Moleculin Biotech common stock, representing approximately 4.99% of the class. This reflects both currently held shares and shares issuable upon warrant exercise, subject to blocker provisions.

How many Moleculin Biotech (MBRX) shares does Intracoastal hold and through warrants?

The reporting persons may be deemed to own 973,927 shares, including 203,720 shares of common stock held by Intracoastal and 770,207 shares issuable upon exercise of Intracoastal Warrant 2. Additional shares under the warrant are excluded due to ownership limits.

What is the role of blocker provisions in Intracoastal’s Moleculin Biotech (MBRX) warrants?

Intracoastal’s warrants contain blocker provisions that prevent exercises increasing beneficial ownership above 9.99% for Intracoastal Warrant 1 and 4.99% for Intracoastal Warrant 2. These limits reduce the number of shares deemed beneficially owned for reporting purposes.

How many Moleculin Biotech (MBRX) shares could Intracoastal own without blocker limits?

Without the blocker provisions, the reporting persons may have been deemed to beneficially own up to 5,333,332 shares of Moleculin Biotech immediately after the Securities Purchase Agreement and 4,203,719 shares as of August 6, 2025, including shares underlying the warrants.

What was Intracoastal’s initial position in Moleculin Biotech (MBRX) after the Securities Purchase Agreement?

Immediately following the Securities Purchase Agreement on July 31, 2026, the reporting persons may have been deemed to beneficially own 788,091 shares of common stock, about 9.99% of the class. This included 775,000 shares to be issued and 13,091 warrant shares tied to Intracoastal Warrant 1.

What is the Moleculin Biotech (MBRX) share count used to calculate Intracoastal’s 4.99% stake?

The reported 4.99% beneficial ownership is calculated using 7,100,713 shares outstanding as of July 30, 2026, plus 11,088,334 shares issued at the closing of the Securities Purchase Agreement, 558,333 shares from exercise of Intracoastal Warrant 1, and 770,207 warrant shares under Intracoastal Warrant 2.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 05:27 PM Accepted by SEC EDGAR 08/06/2026 - 05:26 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Moleculin Biotech, Inc.

(Name of Issuer)

Common stock, par value $0.001 per share

(Title of Class of Securities)

60855D408

(CUSIP Number)

07/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 60855D408

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 973,927.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 948,927.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

973,927.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 60855D408

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 973,927.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 948,927.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

973,927.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 60855D408

1

Names of Reporting Persons

Intracoastal Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 973,927.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 948,927.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

973,927.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Moleculin Biotech, Inc.
(b)	Address of issuer's principal executive offices: 5300 Memorial Drive, Suite 950, Houston, TX 77007
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Common stock, par value $0.001 per share
(e)	CUSIP Number(s): 60855D408
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on July 31, 2026 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 3, 2026), each of the Reporting Persons may have been deemed to have beneficial ownership of 788,091 shares of Common Stock, which consisted of (i) 775,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 13,091 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1"), and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 7,100,713 shares of Common Stock outstanding as of July 30, 2026, as reported to by the Issuer and (2) 775,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 13,091 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 545,242 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock and (II) 3,999,999 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 5,333,332 shares of Common Stock. (ii) As of the close of business on August 6, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 973,927 shares of Common Stock, which consisted of (i) 203,720 shares of Common Stock held by Intracoastal and (ii) 770,207 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 7,100,713 shares of Common Stock outstanding as of July 30, 2026, as reported to by the Issuer, plus (2) 11,088,334 shares of Common Stock in the aggregate issued at the closing of the transaction contemplated by the SPA, (3) 558,333 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1 and (4) 770,207 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes 3,229,792 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 4,203,719 shares of Common Stock.
(b)	Percent of class: 4.99 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 973,927
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 948,927
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	08/06/2026

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	08/06/2026

Intracoastal Capital LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	08/06/2026

Exhibit Information

Exhibit 1 - Joint Filing Agreement